Patents by Inventor Yoshinao Ruike
Yoshinao Ruike has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240052021Abstract: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the ? chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the ? chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.Type: ApplicationFiled: January 20, 2023Publication date: February 15, 2024Inventors: Yoshinao RUIKE, Zenjiro SAMPEI
-
Patent number: 11891434Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.Type: GrantFiled: May 24, 2018Date of Patent: February 6, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Miho Funaki, Naoka Hironiwa, Atsuhiko Maeda, Junichi Nezu, Yoshinao Ruike, Takeshi Baba, Shun Shimizu
-
Publication number: 20230383011Abstract: The present invention relates to Notch receptor-targeting multispecific antigen-binding molecules, uses thereof, etc. The present invention provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety which specifically binds to a Notch receptor on a first target cell, and a second antigen-binding moiety which specifically binds to an anchor antigen on a second target cell. Furthermore, the inventors demonstrate anchorage-dependent Notch signalling activation by the multispecific antigen-binding molecules of the invention.Type: ApplicationFiled: June 30, 2021Publication date: November 30, 2023Inventors: Zhen Ning Adrian WEE, Yoshinao RUIKE, Hiroyasu MURAMATSU, Tomoyuki IGAWA
-
Patent number: 11827699Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.Type: GrantFiled: July 5, 2018Date of Patent: November 28, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Shigero Tamba, Takehisa Kitazawa, Takeshi Baba, Yoshinao Ruike, Junichi Nezu
-
Patent number: 11827717Abstract: The present invention provides anti-MASP-1 (mannan-binding lectin (MBL)-associated serine protease 1) antibodies and methods of using the same. In some embodiments, an anti-MASP-1 antibody of the invention binds to MASP-1 but does not bind to MASP-3. The invention also provides nucleic acids comprising a nucleotide sequence encoding an anti-MASP-1 antibody of the present invention. The invention further provides pharmaceutical compositions comprising an anti-MASP-1 antibody of the present invention and a pharmaceutically acceptable carrier.Type: GrantFiled: April 2, 2018Date of Patent: November 28, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao Ruike, Taku Fukuzawa
-
Patent number: 11597760Abstract: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the ? chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the ? chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.Type: GrantFiled: July 17, 2019Date of Patent: March 7, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao Ruike, Zenjiro Sampei
-
Patent number: 11454633Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.Type: GrantFiled: June 1, 2020Date of Patent: September 27, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao Ruike, Taichi Kuramochi, Hiroyasu Muramatsu, Atsunori Ueyama, Tomoyuki Igawa, Hitoshi Katada, Yuji Hori
-
Publication number: 20220275076Abstract: The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue.Type: ApplicationFiled: May 12, 2022Publication date: September 1, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao RUIKE, Taichi KURAMOCHI
-
Patent number: 11359009Abstract: The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue.Type: GrantFiled: December 22, 2016Date of Patent: June 14, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao Ruike, Taichi Kuramochi
-
Publication number: 20210115154Abstract: The present invention provides anti-MASP-1 (mannan-binding lectin (MBL)-associated serine protease 1) antibodies and methods of using the same. In some embodiments, an anti-MASP-1 antibody of the invention binds to MASP-1 but does not bind to MASP-3. The invention also provides nucleic acids comprising a nucleotide sequence encoding an anti-MASP-1 antibody of the present invention. The invention further provides pharmaceutical compositions comprising an anti-MASP-1 antibody of the present invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 2, 2018Publication date: April 22, 2021Inventors: Yoshinao RUIKE, Taku FUKUZAWA
-
Publication number: 20200317768Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.Type: ApplicationFiled: June 1, 2020Publication date: October 8, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao RUIKE, Taichi KURAMOCHI, Hiroyasu MURAMATSU, Atsunori UEYAMA, Tomoyuki IGAWA, Hitoshi KATADA, Yuji HORI
-
Patent number: 10738111Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.Type: GrantFiled: April 26, 2018Date of Patent: August 11, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao Ruike, Taichi Kuramochi, Hiroyasu Muramatsu, Atsunori Ueyama, Tomoyuki Igawa, Hitoshi Katada, Yuji Hori
-
Publication number: 20200123256Abstract: The present invention provides multispecific antigen-binding molecules that comprise a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity, uses of such multispecific antigen-binding molecules, etc. The present inventors discovered novel multispecific antigen-binding molecules with excellent cellular cytotoxicity and high stability, which comprise a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing RNF43, it is possible to produce novel pharmaceutical compositions comprising the multispecific antigen-binding molecules for treating or preventing various cancers.Type: ApplicationFiled: May 2, 2018Publication date: April 23, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Mayumi Hoshino, Yumiko Kawai, Takahiro Ishiguro, Satoshi Aida, Yoshinao Ruike, Shu Wen Samantha Ho, Shuet Theng Lee
-
Publication number: 20200031913Abstract: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the ? chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the ? chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.Type: ApplicationFiled: July 17, 2019Publication date: January 30, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao RUIKE, Zenjiro SAMPEI
-
Patent number: 10385122Abstract: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the ? chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the ? chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.Type: GrantFiled: June 27, 2018Date of Patent: August 20, 2019Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao Ruike, Zenjiro Sampei
-
Publication number: 20190185557Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn wider an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.Type: ApplicationFiled: July 5, 2018Publication date: June 20, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Shigero Tamba, Takehisa Kitazawa, Takeshi Baba, Yoshinao Ruike, Junichi Nezu
-
Publication number: 20190062413Abstract: An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the ? chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the ? chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.Type: ApplicationFiled: June 27, 2018Publication date: February 28, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao RUIKE, Zenjiro SAMPEI
-
Publication number: 20190002548Abstract: The invention provides anti-myostatin antibodies and methods of using the same. In some embodiments, an isolated anti-myostatin antibody of the present invention binds to mature myostatin, and uptake of the antibody into cells is enhanced when complexed with the antigen. The invention also provides isolated nucleic acids encoding an anti-myostatin antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. Anti-myostatin antibodies of the present invention may be for use as a medicament. Anti-myostatin antibodies of the present invention may be for use in treating a muscle wasting disease. Anti-myostatin antibodies of the present invention may be for use in increasing mass of muscle tissue.Type: ApplicationFiled: December 22, 2016Publication date: January 3, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao RUIKE, Taichi KURAMOCHI
-
Publication number: 20180319876Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.Type: ApplicationFiled: April 26, 2018Publication date: November 8, 2018Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao RUIKE, Taichi KURAMOCHI, Hiroyasu MURAMATSU, Atsunori UEYAMA, Tomoyuki IGAWA, Hitoshi KATADA, Yuji HORI
-
Publication number: 20180319877Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.Type: ApplicationFiled: April 26, 2018Publication date: November 8, 2018Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao RUIKE, Taichi KURAMOCHI, Hiroyasu MURAMATSU, Atsunori UEYAMA, Tomoyuki IGAWA, Hitoshi KATADA, Yuji HORI